New drug combo aims to slow advanced breast cancer

NCT ID NCT04920708

Ongoing Disease control Sponsor: Royal Marsden NHS Foundation Trust Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the experimental drug ipatasertib to standard hormone therapy and targeted drugs can help people with a certain type of advanced breast cancer (ER+/HER2-) live longer without their cancer growing. It includes 57 participants whose cancer did not respond well to initial treatment. The goal is to see if the new combination works better than the standard treatment alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm estrogen-receptor positive breast cancer hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BREAST CANCER ERΑ+ BREAST CANCER METASTATIC BREAST CANCER

Contacts and locations

Locations

Addenbrookes Hospital

Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom
Beatson West of Scotland Cancer Centre

Glasgow, United Kingdom
Imperial College University Hospitals NHS Trust

London, W2 1NY, United Kingdom
Mount Vernon Cancer Centre

London, Surrey, HA6 2RN, United Kingdom
Nottingham City Hospital

Nottingham, United Kingdom
Oxford University Hospitals

Oxford, OX3 7LE, United Kingdom
Royal Cornwall Hospital

Truro, Cornwall, TR1 3LQ, United Kingdom
Royal Free Hospital

London, NW3 2QC, United Kingdom
Royal Marsden NHS Foundation Trust

London, SW3 6JJ, United Kingdom
The Christie NHS Foundation Trust

Manchester, M20 4BX, United Kingdom
University College London Hospital

London, United Kingdom
Velindre Cancer Centre

Cardiff, Wales, CF14 2TL, United Kingdom
Western General Hospital

Edinburgh, EH4 2XU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.